Categories Earnings, Other Industries

CorMedix narrows loss in Q2, revenue miss estimates

CorMedix (NYSE: CRMD) reported mixed second quarter results after the bell. Revenue failed to beat estimates, while earnings came in better-than-expected. Last month, the biopharma firm reported that it has completed the Phase 3 trials for LOCK-IT-100 and is encouraged by the response from the US Food and Drug Administration (FDA). 

Revenue improved to $35,266 compared to $7,551 reported last year while loss per share came in at 3 cents compared to 52 cents reported last year. Analysts were estimating revenue of $130,000 and loss per share of 21 cents. CorMedix also received $5.1 million through the sale of its New Jersey NOL through the Technology Business Tax Certificate program.

Operating expenses decreased 35% primarily due to reduction in Research & Development (R&D) expenses. R&D expenses were down 55% due to reduction of clinical trial expenses, while SG&A expenses rose 32% due to increased staffing and compliance expenses.

Commenting on the Neutrolin trial update, CEO Khoso Baluch said, “We have made significant progress on our goal of bringing Neutrolin to the U.S. market as a catheter lock solution for hemodialysis. Our focus now turns to making sure that we have all of the data and information required to file an NDA and obtain marketing approval.”

Phase 3 Trial Update

CorMedix focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company’s lead product candidate Neutrolin has completed its Phase 3 trials in the US. If the company gets positive feedback from FDA, it expects Neutrolin to get market approval in 2020.

The LOCK-IT-100 Phase 3 trial studies the effectiveness of Neutrolin to be used as a catheter lock solution compared to heparin for the prevention of catheter-related bloodstream infection (CRBSI) for patients who are undergoing hemodialysis.

Currently, FDA is reviewing all the data submitted for the Phase 3 trial. For now, the regulator hasn’t mentioned anything on whether there would be a need for CorMedix to conduct one more trial.

The company also plans to continue its discussions with the FDA relating to the chemistry, manufacturing and controls (CMC) data. It’s worth noting that the CMC data feedback from the regulator is important before the company can initiate pre-new drug application meeting during the fourth quarter of 2019.

Looking Ahead

For the third quarter, the Wall Street is expecting sales to touch $320,000 and loss per share of 24 cents. When it comes to fiscal 2019 estimates, analysts are anticipating revenue of $850,000 and loss per share of 94 cents.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

IPO Alert: Here’s what to look for when CaliberCos goes public

The massive slowdown in the IPO market continued in the second half as the challenges posed by high inflation and interest rate hikes weighed on investor confidence. Meanwhile, there is

CarMax (KMX) Stock: Does the current dip offer a buying opportunity?

The automotive sector is one of the worst affected by the combination of high inflation and rising interest rates. Consumers have become more cautious and are prioritizing their purchases with

Ultimax Digital gears up for $10mln IPO. Here’s all you need to know

The IPO market has witnessed muted activity this year, and things don’t seem to have improved in the second half. The upcoming public listing of video game technology firm Ultimax


  1. Pingback: Heavy-R
  2. Pingback: Heavy
  3. Pingback: ffh4x v41
  4. Pingback: ff tool
  5. Pingback: carihuela
  6. Pingback: maggi
  7. Pingback: TikTok 18
  8. Pingback: Epaviste
  9. Pingback: enlevement epave
  10. Pingback: enlevement epave
  11. Pingback: épave automobile
  12. Pingback: Epaviste
  13. Pingback: ไพ่แคง
  14. Pingback: เว็บ123
  15. Pingback: sa casino
  16. Pingback: Kanha Gummies
  17. Pingback: buy weed online
  18. Pingback: ps5 sale
  19. Pingback: Marijuana delivery
  20. Pingback: Epaviste gratuit
  21. Pingback: enlevement epave
  22. Pingback: cereal milk strain
  23. Pingback: berry pie strain
  24. Pingback: white runtz
  25. Pingback: senzate
  26. Pingback: Buy This Domain
  27. Pingback: fishscale cocaine
  28. Pingback: buy 5-meo-dmt usa
  29. Pingback: classic books
  30. Pingback: Promotional models
  31. Pingback: Miami models
  32. Pingback: Hd Wallpapers
  33. Pingback: Iphone Wallpaper
  34. Pingback: زواج
  35. Pingback: Scotch Whisky
  36. Pingback: Buy This Domain
  37. Pingback: slot
  38. Pingback: slot
  39. Pingback: IRA investment
  40. Pingback: poster 1988
  41. Pingback: rabota v New Yorke
  42. Pingback: art framed
  43. Pingback: slayer sneakers
  44. Pingback: Wood tile floor
  45. Pingback: bathroom tile
  46. Pingback: lowes tiles
  47. Pingback: Buy Cocaine Online
  48. Pingback: zemits review
  49. Pingback: facial equipments
  50. Pingback: Trending news
  51. Pingback: Trending videos
  52. Pingback: Technology news
  53. Pingback: Policy
  54. Pingback: Trending news
  55. Pingback: find this
  56. Pingback: other
  57. Pingback: go to my site
  58. Pingback: discover this
  59. Pingback: like it
  60. Pingback: helpful resources
  61. Pingback: Website
  62. Pingback: colleges egypt
  63. Pingback: Glock 17 for Sale
  64. Pingback: Guns on Sale
  65. Pingback: Colt 1911 for Sale
  66. Pingback: 9mm Ammo
  67. Pingback: Firearms Site
  68. Pingback: 45 ACP Ammo
  69. Pingback: SpyToStyle
  70. Pingback:
  71. Pingback:
  72. Pingback: SpytoStyle.Com
  73. Pingback:
  74. Pingback: minecraft lmhmod
  75. Pingback: emupedia
  76. Pingback: soi cau 247
  77. Pingback: ban ca h5
  78. Pingback: so em xui la gi
  79. Pingback: tải game bài

Comments are closed.


Add Comment
Viewing Highlight